SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.

Shanghai Allist Pharmaceuticals Co., Ltd.

688578

CNE100005XJ7

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-30 pm EDT			5-day change	1st Jan Change
58.12 ^CNY	+0.64%		+2.22%	+39.51%

May. 09	Abbisko Cayman Unit's Cancer Drug To Be Clinically Tested in Combination with Shanghai Allist's Furmonertinib	MT
Apr. 25	Shanghai Allist Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Shanghai Allist Pharmaceuticals Co., Ltd.(XSSC:688578) added to S&P Global BMI Index

September 18, 2023 at 12:00 am EDT

Latest news about Shanghai Allist Pharmaceuticals Co., Ltd.

Abbisko Cayman Unit's Cancer Drug To Be Clinically Tested in Combination with Shanghai Allist's Furmonertinib	May. 08	MT
Shanghai Allist Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Shanghai Allist Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Shanghai Allist Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
Shanghai Allist Pharmaceuticals Co., Ltd.(XSSC:688578) added to S&P Global BMI Index	23-09-18	CI
Allist Pharmaceuticals Co., Ltd. and ArriVent Biopharma, Inc. Announce Interim Results from Ongoing Phase 1B Trial with Furmonertinib At the 2023 World Conference on Lung Cancer	23-09-10	CI
Shanghai Allist Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Shanghai Allist Pharmaceuticals Gets Nod to Advance Trial of Lung Cancer Treatment	23-08-23	MT
Chinese healthcare stocks hit by stepped up anti-graft crackdown	23-08-09	RE
Shanghai Allist Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI

Chart Shanghai Allist Pharmaceuticals Co., Ltd.

Duration

Period

Chart Shanghai Allist Pharmaceuticals Co., Ltd.

More charts

Shanghai Allist Pharmaceuticals Co Ltd is a China-based company focusing on the field of tumor treatment. The Company has built a research and development pipeline in the field of small molecule targeted drugs for non-small cell lung cancer. The Company has established a complete new drug research and development system, covering all aspects of lead drug discovery and optimization, candidate drug evaluation and establishment, drug preclinical and clinical research, drug registration and application, industrialization and commercialization. The Company has a number of research pipeline projects under development, such as vometinib. Its drugs are used in the fields of blood pressure reduction, anti-tumor, anti-diabetic and gastric acid related diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-08-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Shanghai Allist Pharmaceuticals Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

58.12

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.	+39.51%	3.61B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B
INSMED INCORPORATED	+77.64%	8.87B

Bio Therapeutic Drugs